Contineum Therapeutics Inc (CTNM)
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for neuroscience, inflammation, and immunology-related conditions in the United States. Its pipeline includes PIPE-791, a brain-penetrant LPA1 receptor inhibitor being studied for idiopathic pulmonary fibrosis and chronic pain, as well as PIPE-307, a muscarinic type 1 receptor inhibitor under development for depression and relapsing-remitting multiple sclerosis. The company, which was founded in 2009 and is based in San Diego, California, adopted the Contineum Therapeutics name in November 2023 after previously operating as Pipeline Therapeutics, Inc. Contineum Therapeutics common stock trades on NASDAQ under the ticker CTNM.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CTNM
|
$12.81
|
-6.3% Downside
|
Fair
|
$22.33
|
63.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-8.8x
|
2.0x
|
—
|
505.8 M
|
272.4 M
|
1.4%
|
73.8%
|
26.1
|
—
|
98.7%
|
